Literature DB >> 14509955

Optimization of dose distributions for adjuvant locoregional radiotherapy of gastric cancer by IMRT.

Frank Lohr1, Barbara Dobler, Sabine Mai, Brigitte Hermann, Uta Tiefenbacher, Petra Wieland, Volker Steil, Frederik Wenz.   

Abstract

BACKGROUND AND
PURPOSE: Locoregional relapse is a problem frequently encountered with advanced gastric cancer. Data from the randomized Intergroup trial 116 suggest effectiveness of adjuvant radiochemotherapy, albeit with significant toxicity. The potential of intensity-modulated radiotherapy (IMRT) to reduce toxicity by significantly reducing maximum and median doses to organs at risk while still applying sufficient dose to the target volume in the upper abdomen was studied. PATIENT AND METHODS: For a typical configuration of target volumes and organs, a step-and-shoot IMRT plan (eight beam orientations), developed as a class solution for treatment of tumors in the upper abdomen (Figures 1 to 3), a conventional plan, a combination of the conventional plan with a kidney-sparing boost plan, and a conventional plan with noncoplanar ap and pa fields for improved kidney sparing were compared with respect to coverage of target volume and dose to organs at risk with a dose of 45 Gy delivered as the median dose to the target volume.
RESULTS: When using the conventional three-dimensionally planned box techniques, the right kidney could be kept below tolerance, but median dose to the left kidney amounted to between 14.8 and 26.9 Gy, depending on the plan. IMRT reduced the median dose to the left kidney to 10.5 Gy, while still keeping the dose to the right kidney < 8 Gy. Liver was spared better with IMRT. Dose to the lungs was not significantly different, and dose to the spinal cord was higher (but well below tolerance) with IMRT. The dose distribution within the target volume was less homogeneous than for the conventional plans. With regard to target coverage, > 90% of prescription dose were delivered to > 90% of target volume with IMRT (Table 1).
CONCLUSION: IMRT has the potential to deliver efficient doses to target volumes in the upper abdomen, while delivering dose to organs at risk in a more advantageous fashion than a conventional technique. For clinical implementation, the possibility of extensive organ motion in the upper abdomen has to be taken into account for treatment planning and patient positioning. The multitude of potential risks related to its application has to be the subject of thorough follow-up and further studies.

Entities:  

Mesh:

Year:  2003        PMID: 14509955     DOI: 10.1007/s00066-003-1087-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  15 in total

Review 1.  Proton beam therapy for gastrointestinal cancers: past, present, and future.

Authors:  Shahed N Badiyan; Christopher L Hallemeier; Steven H Lin; Matthew D Hall; Michael D Chuong
Journal:  J Gastrointest Oncol       Date:  2018-10

2.  Comparison of dosiology between three dimensional conformal and intensity-modulated radiotherapies (5 and 7 fields) in gastric cancer post-surgery.

Authors:  Hong Ma; Jun Han; Tao Zhang; Yang Ke
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-10-20

3.  Basal renal function reserve and mean kidney dose predict future radiation-induced kidney injury in stomach cancer patients.

Authors:  Guler Yavas; Rengin Elsurer; Cagdas Yavas; Ozlem Ata
Journal:  Support Care Cancer       Date:  2013-10-03       Impact factor: 3.603

4.  Evaluation of dose coverage to target volume and normal tissue sparing in the adjuvant radiotherapy of gastric cancers: 3D-CRT compared with dynamic IMRT.

Authors:  Kk Murthy; Ka Shukeili; Ss Kumar; Ca Davis; Rr Chandran; S Namrata
Journal:  Biomed Imaging Interv J       Date:  2010-07-01

Review 5.  Role of radiation therapy in gastric adenocarcinoma.

Authors:  Lisa Hazard; John O'Connor; Courtney Scaife
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

6.  Dose-dependent changes in renal (1)H-/(23)Na MRI after adjuvant radiochemotherapy for gastric cancer.

Authors:  Stefan Haneder; Johannes Michael Budjan; Stefan Oswald Schoenberg; Simon Konstandin; Lothar Rudi Schad; Ralf Dieter Hofheinz; Veronika Gramlich; Frederik Wenz; Frank Lohr; Judit Boda-Heggemann
Journal:  Strahlenther Onkol       Date:  2014-12-02       Impact factor: 3.621

7.  Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.

Authors:  Xin Wang; Jing Jin; Ye-Xiong Li; Hua Ren; Hui Fang; Shu-Lian Wang; Yue-Ping Liu; Wei-Hu Wang; Zi-Hao Yu; Yong-Wen Song; Xin-Fan Liu
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 8.  Intensity-modulated radiation therapy for gastrointestinal tumors.

Authors:  Jeffrey J Meyer; Brian G Czito; Christopher G Willett
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

9.  Image-guided intensity-modulated radiotherapy for pancreatic carcinoma.

Authors:  Martin Fuss; Adrian Wong; Clifton D Fuller; Bill J Salter; Cristina Fuss; Charles R Thomas
Journal:  Gastrointest Cancer Res       Date:  2007-01

10.  Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.

Authors:  J Boda-Heggemann; C Weiss; V Schneider; R-D Hofheinz; S Haneder; H Michaely; H Wertz; U Ronellenfitsch; A Hochhaus; F Wenz; F Lohr
Journal:  Strahlenther Onkol       Date:  2013-04-06       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.